Can Test Reports for Medical Device Registration in Vietnam Be Reused?

Test reports for medical device registration in Vietnam can often be reused or leveraged, but not automatically. Reuse depends on the target country's regulatory requirements, the device's risk classification, the applicable regulatory pathway, and the existing documentation base. In most cases, a gap assessment is required, and reports may need to be supplemented, reissued, or supported by additional evidence to meet Vietnam's specific requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid project delays caused by unclear classification, missing evidence, or authorization arrangements.

Published: 2026-07-10 16:54 | Updated: 2026-07-10 16:54

This FAQ addresses common questions from medical device companies regarding international registration, documentation preparation, compliance pathways, and post-market maintenance, focusing on the priority judgments needed in actual projects.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Judgment Logic
• Materials and Evidence
• Common Errors
• Preparation Checklist
• AIMEILI View
• Common Follow-up Questions
• Continue Reading
• Applicability Boundaries

Key Summary

For Chinese medical device companies, a prudent approach is to first conduct product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Vietnam registration typically affects technical files, authorized representatives, importer coordination, label language, quality system evidence, and subsequent change maintenance. If the project only focuses on 'which documents to submit' upfront, it is easy to encounter deficiencies or rework related to model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends that companies incorporate this question into a unified strategy for GHWP member states and multi-country market access, using a core set of reusable technical documents to support localization in different markets, rather than recreating documents from scratch for each country.

Applicable Scenarios and Core Questions

Companies searching for 'Can test reports for medical device registration in Vietnam be reused?' are usually not looking for a conceptual explanation, but rather to determine whether existing documentation can support Vietnam submission, whether a local agent or authorized representative is needed, why timelines may be extended, and which issues may affect market launch plans. This question often involves product classification, registration pathways, evidence chains, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for one country alone is not enough. A more valuable approach is to first develop reusable versions of core technical documents, quality system certificates, performance verification, clinical evidence, and labels/instructions, and then localize them according to each country's regulatory requirements.

Registration Judgment Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, body contact method, duration of use, sterility, active status, and whether it includes software or IVD attributes, and then determine the risk classification and submission pathway. Once the pathway is incorrectly determined, subsequent translation, notarization, authorization, testing, and supplementary documentation will all deviate from the correct direction.

For Vietnam projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are vaguely handled only in commercial contracts, they can easily affect market control later.

Materials and Evidence

Common documents include product description, model/specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system certificate, technical file, performance verification report, risk management file, clinical evaluation or clinical evidence, labels/instructions, authorization documents, existing registration certificates, manufacturer's declaration, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. Claims in the instructions, models covered by test reports, scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for its intended use, not on whether the company uploaded many documents.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated NMPA documents without rearranging evidence according to Vietnam's pathway.
• Having too many model specifications but insufficient coverage in test reports, clinical evidence, or labels.
• Selecting a local agent solely based on sales cooperation without clarifying regulatory responsibilities, certificate control, and post-market maintenance obligations.
• Inconsistencies between labels, instructions, promotional materials, and registration claims, leading to deficiencies or post-market compliance risks.
• Failure to plan for multi-country document reuse in advance, resulting in repeated preparation for each country, increasing cost and timeline.

Preparation Checklist

Before starting the project, companies should use an internal checklist to confirm the documentation base to avoid discovering critical evidence gaps after submission.

• Compile a target product list, model/specification matrix, and intended use statement.
• Verify whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English instructions.
• Confirm the responsibilities, fees, certificate control, and exit mechanisms of the local agent or authorized representative.
• Establish a target country gap assessment table to identify content requiring additional testing, translation, notarization, or supplementary declarations.

AIMEILI View

AIMEILI recommends that companies not view Vietnam registration as a one-time document submission, but rather manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical document and evidence matrix first, then converting it according to each country's requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than temporarily supplementing documents country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documents appear numerous, the project may still experience repeated issues during deficiency responses, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic documents be used directly for Vietnam registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

Local agents typically participate in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger to manage product lists, model specifications, registration pathways, document owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This allows for timely identification of documentation gaps and helps management determine whether the project will affect market launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to each country's requirements. In particular, labels/instructions, clinical evaluations, risk management, performance verification, and quality system certificates must maintain consistent versions.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documents are not isolated certificates. Regulatory authorities typically check whether the manufacturer name, production address, product scope, certificate validity, applicable standards, and technical documents are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the production address, model specifications, instruction version, and test reports are inconsistent, even if the company has prepared many documents, supplementary explanations may be required.

Companies should establish an evidence consistency checklist before submission, mapping product names, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management versions, label/instruction versions, and quality system certificates item by item. This action may seem basic, but it can significantly reduce the probability of deficiencies, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibility

Vietnam registration projects typically involve local agents, authorized representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions, and authorization documents cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of documents from scratch.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest significant effort in obtaining the certificate but neglect post-market maintenance. Once production address changes, model expansions, instruction updates, or agent replacements occur, certificates and market sales can become disconnected.

AIMEILI recommends that companies incorporate this question into annual international registration planning: first clarify target market priorities, then establish reusable document packages and country gap lists, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value is not only improving registration efficiency for a single country, but more importantly, enabling companies to develop replicable overseas compliance capabilities, reducing the cost of starting from scratch each time they enter a new market.

Continue Reading

Previous: How to Prepare Clinical Evaluation Documents for Medical Device Registration in Vietnam?

Next: How to Use ISO 13485 Certificate for Medical Device Registration in Vietnam?

Recommended Reading:

• How to Prepare Registration Documents for Medical Device Registration in Malaysia?
• How to Determine Product Classification for Medical Device Registration in Malaysia?
• How to Organize Technical Files for Medical Device Registration in Malaysia?
• How to Localize Labels and Instructions for Medical Device Registration in Malaysia?
• How to Prepare Clinical Evaluation Documents for Medical Device Registration in Malaysia?
• Can Test Reports for Medical Device Registration in Malaysia Be Reused?

Return to FAQ Center

News

Contact AIMEILI

Content Review and Applicability Boundaries

Content Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory information; industry media and project experience are used only as auxiliary judgment.

Applicability Boundaries: This article is for preliminary understanding, documentation preparation, and project planning, and does not replace the official requirements of the target country's regulatory authority, test conclusions, or legal advice.